文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

骨髓保护放疗对局部晚期宫颈癌患者急性血液学毒性的影响:一项前瞻性II期随机对照研究

Effects of bone marrow sparing radiotherapy on acute hematologic toxicity for patients with locoregionally advanced cervical cancer: a prospective phase II randomized controlled study.
PubMed 文献 · Radiat Oncol · 2024-04-09

该研究前瞻性纳入242例局部晚期宫颈癌患者并随机分为骨髓保护(BMS)组和对照组,BMS组额外要求骨髓V40<25%。结果显示BMS组急性血液学毒性、白细胞减少和中性粒细胞减少的发生率均显著低于对照组,骨髓V40是≥3级急性血液学毒性的独立危险因素。

要点

  • BMS组≥2级急性血液学毒性发生率为72.70%,对照组为90.90%,差异有统计学意义(P<0.001)。
  • BMS组≥3级急性血液学毒性发生率为16.50%,对照组为65.30%,差异有统计学意义(P<0.001)。
  • 骨髓V40是≥3级急性血液学毒性的独立危险因素(OR=2.734,95%CI 1.959-3.815,P<0.001),截断值为25.036%。

核心结论

  • 接受骨髓保护盆腔放疗可降低局部晚期宫颈癌患者急性血液学毒性的发生率,骨髓V40<25%可能是降低急性血液学毒性风险的重要因素。

研究设计与样本

  • 前瞻性II期随机对照研究,于2021年5月至2022年5月在单中心招募局部晚期宫颈癌患者,并随机均分为骨髓保护组和对照组。
  • 所有患者接受盆腔放疗联合同步顺铂(40 mg/m2每周),随后接受近距离放疗;骨髓保护组额外要求骨髓V40<25%。
  • 共242例患者纳入分析,急性血液学毒性每周评估一次;试验注册号为ChiCTR2200066485。

主要发现

  • 在意向治疗人群中,骨髓保护组与对照组的≥2级急性血液学毒性发生率分别为72.70%和90.90%(P<0.001),≥3级分别为16.50%和65.30%(P<0.001)。
  • 骨髓保护组与对照组的≥2级白细胞减少发生率分别为66.10%和85.10%(P=0.001),≥3级分别为13.20%和54.50%(P<0.001)。
  • 骨髓保护组与对照组的≥2级中性粒细胞减少发生率分别为37.20%和66.10%(P<0.001),≥3级分别为10.70%和43.80%(P<0.001)。
  • 骨髓保护组还降低了直肠、膀胱及左右股骨头等危及器官的受照剂量。
  • 单因素和多因素分析显示骨髓V40是≥3级急性血液学毒性的独立危险因素(OR=2.734,95%CI 1.959-3.815,P<0.001),截断值为25.036%,曲线下面积为0.786;构建的列线图经严格评估和内部交叉验证显示良好的预测性能。

关键数值与推荐

  • 骨髓保护组额外处方要求骨髓V40<25%。
  • 骨髓V40是≥3级急性血液学毒性的独立危险因素,OR=2.734(95%CI 1.959-3.815,P<0.001),截断值25.036%,AUC=0.786。

临床怎么用

  • 对于接受盆腔放疗的局部晚期宫颈癌患者,骨髓保护放疗可降低急性血液学毒性发生率。
  • 骨髓V40<25%可能是降低急性血液学毒性风险的重要因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate effects of bone marrow sparing (BMS) radiotherapy on decreasing the incidence of acute hematologic toxicity (HT) for locoregionally advanced cervical cancer (LACC) patients treated by pelvic irradiation. MATERIALS AND METHODS: LACC patients were recruited prospectively from May 2021 to May 2022 at a single center and were evenly randomized into the BMS group and the control group. All patients received pelvic irradiation with concurrent cisplatin (40 mg/m2 weekly), followed by brachytherapy and BM V40 < 25% in the BMS group was additionally prescribed. Acute HT was assessed weekly. Binary logistic regression model and receiver operating characteristic (ROC) curve were used for predictive value analysis. The trial was registered with Chinese clinical trial registry (ChiCTR2200066485). RESULTS: A total of 242 patients were included in the analysis. Baseline demographic, disease and treatment characteristics were balanced between the two groups. In the intention-to-treat population, BMS was associated with a lower incidence of grade ≥ 2 and grade ≥ 3 acute HT, leukopenia and neutropenia s(72.70% v 90.90%, P < 0.001*; 16.50% vs. 65.30%, P < 0.001*; 66.10% vs. 85.10%, P = 0.001*; 13.20% vs. 54.50%, P < 0.001*; 37.20% vs. 66.10%, P < 0.001*; 10.70% vs. 43.80%, P < 0.001*). BMS also resulted in decreased dose delivered to the organs at risk (OARs) including rectum, bladder and left and right femoral head. Univariate and multivariate analyses showed that BM V40 was an independent risk factor for grade ≥ 3 acute HT (odds ratio [OR] = 2.734, 95% confidence interval [CI] = 1.959-3.815, P < 0.001*). Cutoff value was 25.036% and area under the curve (AUC) was 0.786. The nomogram was constructed, which was rigorously evaluated and internally cross-validated, showing good predictive performance. CONCLUSIONS: Receiving BMS pelvic irradiation could reduce the incidence of acute HT in LACC patients, and BM V40 < 25% may be a significant factor in reducing the risks of acute HT.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Li W, Ma L, Li F, et al. Effects of bone marrow sparing radiotherapy on acute hematologic toxicity for patients with locoregionally advanced cervical cancer: a prospective phase II randomized controlled study. Radiat Oncol. 2024. PMID: 38594678. doi:10.1186/s13014-024-02432-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。